The Western world’s 1st gene therapy will not return to the European market after its 5-year conditional approval expires on Oct. 25 this year, according to UniQure (NSDQ:QURE).
The company’s Glybera product will only be available for patients who were approved for treatment and reimbursement before Oct. 25, UniQure partner Chiesi said today.
Get the full story at our sister site, Drug Delivery Business News.
The post UniQure pulls first gene therapy from market in Europe appeared first on MassDevice.
from MassDevice http://ift.tt/2pWO3wf
Cap comentari:
Publica un comentari a l'entrada